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ARTICLE
Structural characterization of a highly-potent V3-
glycan broadly neutralizing antibody bound to
natively-glycosylated HIV-1 envelope
Christopher O. Barnes 1, Harry B. Gristick 1, Natalia T. Freund 2,5, Amelia Escolano 2, Artem Y. Lyubimov 3,
Harald Hartweger 2, Anthony P. West Jr.1, Aina E. Cohen 3, Michel C. Nussenzweig 2,4 & Pamela J. Bjorkman 1
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform
HIV-1 vaccine design efforts. Developing bNAbs with increased efficacy requires
understanding how antibodies interact with the native oligomannose and complex-type
N-glycan shield that hides most protein epitopes on HIV-1 envelope (Env). Here we present
crystal structures, including a 3.8-Å X-ray free electron laser dataset, of natively glycosylated
Env trimers complexed with BG18, the most potent V3/N332gp120 glycan-targeting
bNAb reported to date. Our structures show conserved contacts mediated by common
D gene-encoded residues with the N332gp120 glycan and the gp120 GDIR peptide motif, but
a distinct Env-binding orientation relative to PGT121/10-1074 bNAbs. BG18’s binding
orientation provides additional contacts with N392gp120 and N386gp120 glycans near the
V3-loop base and engages protein components of the V1-loop. The BG18-natively-
glycosylated Env structures facilitate understanding of bNAb–glycan interactions critical for
using V3/N332gp120 bNAbs therapeutically and targeting their epitope for immunogen
design.
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In the ongoing fight against the HIV-1 pandemic, the discoveryand characterization of broadly neutralizing antibodies(bNAbs) against HIV-1 envelope (Env) fuel new efforts in
treatment and management of infection. Next-generation bNAbs
protected against and reduced viral loads in humanized mouse1,2
and non-human primate3,4 models of infection and exhibited
anti-viral activity in human trials5–9. Therefore, a vaccine that
elicits such antibodies is likely to be efficacious. Despite their
promise, unusual properties of HIV-1 bNAbs—such as a high
degree of somatic hypermutations10, long heavy chain com-
plementarity determining region 3 (CDRH3) loops11, and/or
short light chain complementarity determining region 3 (CDRL3)
loops12—have made it difficult to elicit bNAbs by immunization.
In addition, innate features of the viral Env spike that interfere
with broad-based immunity include the diversity of Env
sequences that arise by mutation13, a low Env density on the
virion surface that interferes with bivalent antibody binding14,15,
and host glycans that shield most of the Env surface16.
The glycan shield comprises ~50% of the mass of HIV-1 Env, a
(gp120-gp41)3 trimer, and consists of N-glycans attached to an
average of 30 ± 3 potential N-linked glycosylation sites (PNGSs)
per gp120-gp41 protomer17. The carbohydrates decorating the
surface of Env reduce access to protein epitopes and are generally
non-immunogenic because they are assembled by host cell
machinery16. Although under-processed oligomannose N-glycans
cover parts of HIV-1 Env such as the N332gp120 glycan region of
gp120, processed complex-type N-glycans predominate in other
regions of Env18 and protect the CD4 binding site (CD4bs) and
the variable loop 3 (V3-loop) of gp12019. The production of
soluble native-like Env trimers (SOSIPs)20 has enabled structure
determinations of glycosylated Env–bNAb complexes and a better
understanding of bNAb epitopes11,21–24. However, structural
information pertaining to bNAb recognition of highly glycosy-
lated HIV-1 Env trimers in the context of native glycan shields
has been difficult to obtain due to chemical and conformational
heterogeneity of N-glycans that usually precludes crystallization
required for an X-ray structure determination. Thus with one
exception25, all monomeric and trimeric Env crystal structures
were solved using glycoproteins produced with exclusively high
mannose-only forms of N-glycans, which were usually enzyma-
tically trimmed after being complexed with antibody Fabs22,26–37.
A single-particle cryo-electron microscopy (cryo-EM) structure of
a natively glycosylated HIV-1 Env showed complex-type N-gly-
cans at the gp120-gp41 interface, but many of the remaining
glycans were not ordered in the EM map38,39.
The V3/N332gp120 class of HIV-1 bNAbs, exemplified by the
PGT121/10-1074 family40,41, evolved to interact with both glycan
and protein components on HIV-1 Env to effect the neutraliza-
tion of a majority of HIV-1 strains31,42–44. These bNAbs possess
long CDRH3s that interact with the N332gp120 glycan and
penetrate the glycan shield to contact the conserved 324GD/
NIR327 peptide motif at the base of the gp120 V3-loop25,32,42,45.
bNAbs against the V3/N332gp120 site isolated from several HIV-
1-infected donors can adopt different Env-binding orientations to
engage the conserved epitope29,44 and display a wide array of
interactions with surrounding glycans, including glycans at
positions N301gp120 (the PGT128 bNAb), N137gp120/N156gp120/
N301gp120 (PGT121/10-1074 family), and N386gp120/N392gp120
(PGT135). While under-processed N-glycans presenting as a
oligomannose patch predominate in the V3/N332gp120 epitope,
the recent structure of 10-1074 bound to a natively glycosylated
BG505 SOSIP trimer included complex-type N-glycans at
positions N156gp120 and N301gp12025, and sialic acid-bearing
complex-type glycans at the N156gp120 position were shown to be
critical for maturation of the CAP256 V2 apex bNAb lineage46.
Thus, providing structural information of bNAbs bound to Env
trimers that include both complex-type and high mannose
glycans will facilitate developing strategies for improving bNAb
breadth and for design of high-affinity germline-binding
immunogens.
BG18 exhibits the highest potency among the V3/N332gp120
bNAbs described to date47. Isolated from an elite controller
infected with clade B HIV-1, BG18 displays a similar breadth of
coverage (~64%) across a panel of HIV-1 strains to the PGT121/
10-1074 family bNAbs (Supplementary Figure 1), but BG18
neutralizes these strains with a geometric mean IC50 value of 0.03
µg/mL, a higher potency than 10-1074 and other bNAbs in
human clinical trials8. The structure of unliganded BG18 Fab47
exhibited a cleft between the CDRH2 and CDRH3 loops and a
long CDRH3 loop that forms a two-stranded β-sheet as pre-
viously observed for PGT121 and 10-1074 Fab structures solved
in the absence of HIV-1 Env40. However, comparison of the
BG18 Fab structure (PDB 5UD9 (https://doi.org/10.2210/
pdb5UD9/pdb)) with structures of unbound PGT121 and 10-
1074 Fabs (4FQ1 (https://doi.org/10.2210/pdb4FQ1/pdb) and
4FQ2 (https://doi.org/10.2210/pdb4FQ2/pdb)) demonstrated
structural differences including: (1) a displaced, shorter, and more
compact CDRH3 stabilized by a network of hydrogen bonds, (2)
differences in variable light (VL) domain orientation relative to
the variable heavy (VH) domain, and (3) a second cleft in the
antigen-binding site between CDRH3 and CDRL1/CDRL3. In
addition, single-particle electron microscopy showed that BG18
exhibited a different orientation compared with PGT121/10-1074
and other V3/N332gp120 bNAbs for binding HIV-1 Env47.
To better understand the molecular mechanism underlying
BG18’s interactions with Env glycans and increased potency
compared with other V3/N332gp120 bNAbs, we determined the
crystal structures of natively glycosylated clade A (BG505) and
clade B (B41) Envs in complex with BG18 Fab. We used the
increased brightness of an X-ray free electron laser48 (XFEL) to
circumvent the limitations of crystal size and improve the
resolution to 3.8 Å for our BG18-BG505-35O22 complex. We
found that BG18 binds the V3/N332gp120 glycan site in a distinct
manner relative to PGT121-like bNAbs, primarily through
rearrangements in its VH and VL domains. Analysis of BG18
interactions bound to a natively glycosylated Env showed
engagement with oligomannose glycans near the base of the
V3-loop and the conserved GDIR peptide motif. Moreover,
BG18’s CDRL1 and CDRL2 formed part of a cleft within 8 Å of
gp120’s variable loop 1 (V1-loop), increasing BG18’s protein
surface contact with Env. These structures provide valuable
information for understanding the promiscuity of V3/N332gp120
glycan-directed bNAbs that will facilitate current efforts to
evaluate them for therapeutic use in HIV-1-infected humans8 and
to target their epitope for immunogen design49,50.
Results
Structures of natively glycosylated Env-BG18 complexes.
Structural insight into BG18 binding in the context of a natively
glycosylated Env was achieved by crystallizing bNAb Fabs
complexed with Env trimers expressed and purified from Chinese
hamster ovary (CHO) cells51, which include similar glycoforms as
Env trimers expressed in human cell lines52. Our crystals
comprised natively glycosylated Env SOSIP.664 trimers from
clade A (BG505) or clade B (B41) strains bound to Fabs from
BG18 and either 35O22, a gp120–gp41 interface-spanning
bNAb53, or IOMA, a VH1-2 CD4bs bNAb25. We solved the
structures of BG18-BG505-35O22, BG18-B41-35O22, and
BG18-BG505-IOMA complexes to resolutions of 4.1, 4.9, and
6.7 Å, respectively (Fig. 1 and Table 1) by molecular replacement
(Methods) using synchrotron radiation datasets. Subsequently,
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XFEL diffraction data collected by manually targeting individual
crystals (~75 µm × 75 µm × 50 µm dimensions) improved inten-
sities of high-angle Bragg reflections (Supplementary Figure 2) as
previously observed for XFEL datasets48,54, resulting in a 3.8 Å
resolution structure of the BG18-BG505-35O22 complex from
520 still diffraction images (Fig. 1a). The use of B-factor
sharpening55 in our BG18-BG505-35O222 structures permitted
visualization and refinement of most amino acid side chains,
particularly at the Fab–Env interface.
The BG18-BG505-35O22, BG18-B41-35O22, and BG18-
BG505-IOMA structures each comprised an Env trimer bound
to three BG18 Fabs and three 35O22 or IOMA Fabs (Fig. 1a–c),
with ordered electron density corresponding to native glycans at
the Fab interfaces (Fig. 1d and Supplementary Figure 3a). The
orientations of BG18 Fab with respect to gp120 were preserved
across the three crystal structures and a low-resolution EM
structure of a BG18-BG505 complex47 (Supplementary
Figure 3b–d), indicating that the orientation was conserved
across different Env strains and was not an artifact of crystal
packing (Supplementary Figure 3e,f). In addition, BG18 did not
alter binding modes at the gp41/gp120 interface and CD4bs by
35O22 or IOMA, respectively, as these Fabs adopted similar
conformations as previously observed on trimeric Envs25,27.
Superimposition of the BG18 VH-VL coordinates in the
BG18-BG505-35O22 structure with VH-VL in unbound BG18
Fab (PDB 5UD9 (https://doi.org/10.2210/pdb5UD9/pdb))
resulted in a 1.3-Å root mean square deviation (rmsd) (240 Cα
atoms), demonstrating that BG18 CDR loops (except for CDRL2,
which was disordered in unbound BG1847) did not undergo large
conformational rearrangements upon binding Env, and thereby
maintained the previously observed clefts (Fig. 2a, b). Most
notably, the conformation and location of CDRH3 in unbound
BG18, which differs from CDRH3s in unbound PGT121 and
10-107440,47, were preserved in the Env-bound BG18 structure
(Fig. 2c, d). Additionally, interactions with gp120 and glycans at
the base of the V3-loop resulted in stabilization of CDRL2.
BG18 adopts a distinct Env-binding orientation. A low-
resolution Env-bound BG18 structure derived by negative stain
EM showed an orientation for BG18 distinct from the orienta-
tions of 10-1074 and other V3/N332gp120 bNAbs47. Despite
crystallization contacts involving Fabs (Supplementary Figure 3e,
f), BG18 maintained this distinct orientation in our crystal
structures compared with orientations in structures of HIV-1 Env
trimers with Fabs from 10-1074, PGT122, a PGT121 inter-
mediate, and PGT12425,27,31,50 (Fig. 3 and Supplementary Fig-
ure 4). To analyze these differences, we calculated the rotation
and translation for VH-VL domains of Env-bound BG18 Fab
when compared to Env-bound 10-1074 Fab structures. We found
that the mature BG18 VH-VL domains differed by ~78˚ relative to
the orientations of 10-1074 Fab VH-VL domains (Fig. 3d, e),
which contrasts with the ~5˚ difference between Env-bound
PGT122 and 10-1074 Fab orientations. Notwithstanding its
different orientation, BG18, 10-1074, and PGT121-like bNAbs
share a common mode of interaction with the N332gp120 glycan
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Fig. 1 Crystal structures of natively glycosylated HIV-1 Env trimers complexed with BG18. a Cartoon representation of the 3.8 Å structure of BG505 Env
(gp120, light gray; gp41, dark gray) in complex with BG18 (blue) and 35O22 (orange) Fabs. Ordered, native high-mannose glycans (cyan) are represented
as sticks, and complex-type glycans (salmon) are shown as spheres. b 4.9 Å structure of B41 Env bound to BG18 (blue) and 35O22 (orange). Glycans
shown as cyan spheres. c 6.7 Å structure of BG505 Env bound to BG18 (blue) and IOMA (green) Fabs. Glycans were not modeled due to the limited
resolution. d Close-up of the BG18 binding site (VH in dark blue, VL in light blue superimposed on the final 2Fo−Fcalc electron density map contoured at 1.2σ)
on the surface of gp120 (gray) from the BG18-BG505-35O22 structure. Ordered glycans (cyan) near the BG18 binding site are represented as sticks
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through their CDRH3 loops (Fig. 3c). This interaction includes a
structural motif with a consensus R-I-Y-G-V/I-I sequence (BG18
residue numbers 101-106 and 10-1074/PGT122 residue numbers
100-100E; Fig. 2d) encoded by the same antibody D3-3 gene
segment, likely explaining the nearly identical N332gp120 glycan
recognition. Given that CDRH3 is a primary determinant of the
interactions of V3/N332gp120 bNAbs with Env trimer29,32,40,44, its
displacement in both unbound and Env-bound BG18 (Fig. 2c)
rationalizes its orientation of Env binding relative to other V3/
N332gp120 bNAbs. Consistent with these observations, BG18’s
footprint at the V3/N332gp120 epitope differs from PGT121/10-
1074-like bNAbs, such that its interactions with Env glycans and
protein components are mediated by different CDR loops relative
to the CDR loops used by 10-1074 (Fig. 4a, b and Supplementary
Figure 5).
N-linked glycan interpretation and interactions with BG18.
Modeling of glycans was achieved in our structures by inter-
preting electron density at PNGSs using 2Fo−Fc maps calculated
with model phases and in composite annealed omit maps to
reduce model bias56. In the BG18-BG505-35O22 structures, 17 N-
linked glycans were modeled into ordered electron density,
forming glycan arrays that extended ~22 Å from the Env surface
(Fig. 1a and Supplementary Figure 6). N-glycans near the BG18
and 35O22 interfaces were modeled as mostly oligomannose
(Man5-9GlcNAc2) in our structures to avoid over-interpretation
of the electron density, except for complex-type glycans at
positions N88gp120 and N156gp120, which were assigned as
complex-type based on density for a core fucose in our 3.8 Å
XFEL structure (Supplementary Figure 7). Although complex-
type N-glycans were modeled at positions N160gp120, N276gp120,
N301gp120, and N392gp120 in a previous natively glycosylated
10-1074-Env-IOMA structure25 and observed at positions
N160gp120, N197gp120, and N276gp120 by mass spectro-
metry18,52,57, our datasets did not show characteristic densities
for complex glycans at these positions. Modeling of oligomannose
N-linked glycans into ordered electron density was also possible
in the 4.9 Å BG18-B41-35O22 structure, and for the N332gp120
glycan in the 6.7 Å BG18-BG505-IOMA structure (Fig. 1b,c and
Supplementary Figure 6). Overlay of BG505 and B41 Env struc-
tures showed conservation of the glycan shield surrounding the
BG18 binding site (Supplementary Figure 6). Despite resolution
limitations that necessitated glycan modeling as predominantly
oligomannose at PNGSs shown to attach complex glycoforms, the
use of natively glycosylated Env trimers in the crystallization
complexes ensured accuracy of bNAb binding orientations and
interfaces with Env trimer.
As seen in other PGT121-like bNAb-Env SOSIP struc-
tures25,27,31,50, BG18’s primary interaction was with the
N332gp120 glycan (Man9GlcNAc2), which interfaced with
CDRH3, CDRH1, and CDRL2 (Fig. 4a,c; 1170 Å2 total buried
surface area (BSA)). This contrasts with PGT121-like bNAb
interactions that pack the N332gp120 glycan into a groove between
CDRH3 and CDRL1/225,29,31 (Fig. 4b). Indeed, the observed
differences in the orientation of the BG18 Fab light chain on Env
influenced the N332gp120 glycan conformation, as the glycan D1
arm reached in close proximity to CDRL2 and the gp120 GDIR
motif in the BG18-BG505 complex (Fig. 4c), which differs from
the interactions of the N332gp120 glycan D1 arm with light chain
framework region 3 (FWRL3) in the 10-1074-BG505 complex
Table 1 Data collection and refinement statisticsa,b,c
BG18-BG505-35O22 (LCLS:
MFX) PDB 6CH7
BG18-BG505-35O22 (SSRL:
12-2) PDB 6CH8
BG18-B41-35O22 (SSRL 12-
2) PDB 6CH9
BG18-BG505-IOMA (SSRL
12-2) PDB 6CHB
Data collection
Space group H32 H32 H32 P43212
Cell, Å (a, b, c) 238.9, 238.9, 354.0 239.2, 239.2, 355.3 241.6, 241.6, 344.5 175.1, 175.1, 454.4
Angles (α, β, γ) 90, 90, 120 90, 90, 120 90, 90, 120 90, 90, 90
Wavelength 1.309 Å 1.00 Å 1.00 Å 1.00 Å
Resolution (Å) 49.66–3.80 39.5–4.10 39.8–4.95 39.81–6.78
(3.87–3.80) (4.32–4.10) (5.54–4.95) (7.58–6.78)
Rpim (%) – 7.4 (84.1) 8.1 (113.7) 14.2 (139.5)
Rmerge (%) 53.4 (91.5) – – –
I/σI 4.31 (0.32) 8.2 (1.1) 5.5 (0.8) 5.6 (1.2)
Completeness (%) 99.1 (93.8) 99.8 (99.9) 99.8 (99.9) 99.4 (99.6)
Multiplicity 9.2 (3.2) 11.9 (12.2) 9.9 (9.8) 18.5 (19.3)
CC1/2 95.9 (35.4) 99.7 (61.3) 99.6 (45.3) 98.7 (64.8)
Refinement statistics
Resolution (Å) 49.66–3.80 39.5–4.10 39.8–4.85 39.81–6.78
(3.87–3.80) (4.32–4.10) (5.31–4.85) (7.58–6.78)
Reflections
Measured 354394 366818 166902 238633
Unique 38101 30813 18521 13801
Rwork/Rfree 24.3/25.7 25.3/26.7 29.4/31.8 37.9/39.1
Wilson B-factor (Å2) 159.8 141.8 261.8 368.3
Number of atoms
Protein 11,228 11,162 11,151 33,018
Carbohydrate 842 799 779 264
R.m.s deviations
Bond lengths (Å) 0.004 0.008 0.011 0.013
Bond angles (˚) 0.837 0.945 0.913 1.450
a X-ray free electron data were collected at the Linac Coherent Light Source (LCLS) on Macromolecular Femtosecond Crystallography (MFX) instrument. The XFEL dataset averaged diffraction data from
approximately 400 crystals. Conventional synchrotron radiation datasets were collected at the Stanford Synchrotron Radiation Lightsource (SSRL) beamline 12-2, with each dataset generated from a
single crystal
b Numbers in parentheses correspond to the highest resolution shell
c Resolution limits were extended to include weak intensity data68
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(Fig. 4b). Modeling of Env-bound 10-1074 Fab conformation
onto the gp120 subunit from the BG18-BG505-35O22 structure
showed clashes between the N332gp120 glycan and the CDRL1/2
loops and FWRL3 of 10-1074 (Fig. 4d), suggesting that the
distinct BG18 interaction with Env stabilizes a N332gp120 glycan
conformation that is not possible when binding PGT121/10-
1074-like bNAbs29,31.
In addition to the BG18 interaction with the N332gp120 glycan,
BG18 makes secondary interactions with the N392gp120,
N386gp120, and N156gp120 glycans (Fig. 4a and Supplementary
Data 1). These interactions are in contrast with PGT121-like
bNAbs that interact with the N137gp120, N156gp120 glycans in the
V1-loop, and N301gp120 glycans at the base of the V3-loop
(Fig. 4b and Supplementary Data 1)25,27,32. When comparing the
BG18–Env interaction with the only other structure of a V3/
N332gp120 bNAb bound to natively glycosylated Env (10-
1074–BG505)25, the rearrangement of BG18’s VL domain reduced
BG18’s contact with the N301gp120 glycan (modeled as a core
pentasaccharide in the BG18-BG505-35O22 structure) compared
to 10-1074’s contacts with the N301gp120 glycan (modeled as
complex-type biantennary in the 10-1074-BG505-IOMA struc-
ture; PDB 5T3X (https://doi.org/10.2210/pdb5T3X/pdb)) (Fig. 4a,
b). Interestingly, VL domain rearrangements allowed BG18
engagement of the N392gp120 glycan through its CDR loops
(Fig. 4a). The N392gp120 glycan threads between the BG18 cleft
that is located between CDRH3 and CDRL1/L347 (Fig. 2b),
burying ~425 Å2 of Fab surface area against the glycan. This
interaction resembles the PGT135 interaction with monomeric
gp120 in which ~550 Å2 of gp120 surface area is buried against
the N392gp120 glycan44. However, in contrast to PGT135, which
does not neutralize strains lacking the N392gp120 or N386gp120
glycans, BG18 remains potent against strains lacking glycans at
these positions, showing only a ~4-fold reduction in potency
(Table 2). Moreover, binding affinities determined by surface
plasmon resonance (SPR) showed no effect when the N392gp120
glycan was removed from BG505 SOSIP (Supplementary
Figure 8). These results are comparable to PGT121-like bNAbs,
which equivalently neutralize strains +/− the N392gp120 and
N386gp120 glycans (Table 2), suggesting that BG18 combines
binding and neutralization properties of both PGT121-like and
PGT135-like bNAbs.
Molecular details of BG18–Env interactions. BG18 conserves
interactions with the gp120 GDIR peptide motif at the base of the
V3-loop that are seen in other V3/N332gp120 bNAbs (Fig. 5a, b
and Supplementary Figure 5). However, rotation of BG18’s light
chain relative to other V3/N332gp120 bNAbs places only CDRL2
in close proximity to the gp120 GDIR peptide motif, compared to
engagement of GDIR by multiple CDR loops and framework
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Fig. 2 Comparison of apo- and Env-bound BG18 variable domains. a Superposition of VH-VL domains (230 Cα atoms) of unliganded BG18 (deep teal; PDB
5UD9 (http://dx.doi.org10.2210/pdb5UD9/pdb)) with BG18 in the BG18-BG505 structure (blue) showed conservation of the BG18 antigen-binding site
and ordering of CDRL2 in the BG505-bound structure (dashed red line represents disordered CDRL2 in unliganded BG18). b Surface representation of BG18
in the BG505-bound structure showed conservation of BG18 clefts, including the cleft between CDRH3 and CDRL1/3 loops observed in the BG18 apo
structure47. c Ribbon and cartoon representation of the overlay between BG18 (aligned on the Fab VH domains) in the BG18-BG505-35O22 complex
(blue), unliganded BG18 (deep teal), and unliganded 10-1074 (magenta; PDB 4FQ2 (http://dx.doi.org10.2210/pdb4FQ2/pdb)). CDRH3 loops for the three
structures are represented as cartoons. Inset: overlay of BG18-BG505 and 10-1074-BG505 (PDB 5T3Z (http://dx.doi.org10.2210/pdb5T3Z/pdb)) CDRH3
loops. d Cartoon and stick representation of BG18 CDRH3 recognition of the N332gp120 glycan. BG18 residues comprising a conserved structural motif (R-I-
Y-G-V/I-I) are labeled. Electron density contoured at 1σ from 2Fobs−Fcalc composite annealed omit map calculated with phases from models with the
N332gp120 glycan and BG18 CDRH3 coordinates omitted to reduce potential phase bias (cyan and blue mesh)
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regions observed in 10-1074/PGT121-like bNAb recognition
(Fig. 5b, c)25,29,31. These differences in light chain interactions
reflect the germline origins of the BG18 and PGT121/10-1074
light chains, which derive from different VL gene segments
(Fig. 5d). However, in an example of convergence toward a
common chemical binding mechanism, light chain residues
involved in GDIR recognition by BG18 CDRL2 derive from
hypermutation from the germline LV3-25*02 gene segment,
whereas serines in the CDRL3s of PGT121 and 10-1074 derive
from J regions chosen during V–J joining.
B41 Env harbors a GNIR sequence instead of GDIR, allowing
us to analyze the D325Ngp120 substitution in our BG18-B41-
35O22 structure. Side chain placement was not possible due to
low resolution (4.9 Å), but the BG18 interaction with B41
resembled its interaction with BG505 in the BG18-BG505-35O22
structure (Supplementary Figure 9), suggesting that BG18
recognizes the GNIR motif analogously to how it recognizes
GDIR. Consistent with this result, analysis of BG18 neutralization
of HIV-1 isolates containing GNIR motifs showed only a 2-fold
loss in potency, by contrast to PGT121 or PGT122, which showed
~6-fold and ~44-fold losses, respectively (Table 2). However,
while BG18 S53LC potentially engages N325gp120 (Supplementary
Figure 8b), the loss of BG18 Q54LC contacts resulted in the
disorder of CDRL2 residues 54-60 in our BG18-B41 structure.
Further comparisons between BG18-Env and 10-1074-Env
bound structures showed that BG18 CDR loops and light chain
framework region 3 are located in close proximity to the gp120
V1-loop (residues 126–158, Supplementary Figure 5), of which
residues 140–150 were disordered in the BG18–Env structures
(Fig. 6a) and other Env structures22,25,27,31. Despite variability in
V1 across HIV-1 Envs, we observed engagement of V1-loop
protein components with BG18 CDRL2 and FWRL3 residues
(Fig. 6b), accommodating the V1-loop into the nearby positively
charged cleft formed by CDRH3, CDRL1/L2, and FWRL3 loops
(Fig. 6b, c). The electronegativity of this cleft potentially increases
protein–protein interactions with BG505 and other HIV-1 strains
harboring polar or acidic residues in this region (Fig. 6c).
Although PNGSs are commonly found in the V1-loop, the
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Fig. 3 Distinct orientation on HIV-1 Env of BG18 compared to other V3/N332gp120 bNAbs. BG18 Fab (blue, surface) orientation on gp120 (gray, surface)
overlaid with 10-1074 (a, magenta; PDB 5T3Z (http://dx.doi.org10.2210/pdb5T3Z/pdb)) and PGT122 (b, yellow; 5FYL (http://dx.doi.org10.2210/
pdb5T3Z/pdb)) and PGT122 (b, yellow; 5FYL (http://dx.doi.org10.2210/pdb5FYL/pdb)) Fabs. c Overlay of CDRH3 loop of BG18 (blue), 10-1074
(magenta), PGT122 (yellow), PGT121 precursor (red; PDB 5CEZ (http://dx.doi.org10.2210/pdb5CEZ/pdb)), and PGT124 (orange; PDB 4R2G
(http://dx.doi.org10.2210/pdb4R2G/pdb)) after alignment of bound gp120s (gray, surface) demonstrating a conserved structural motif recognizing the
N332gp120 glycan (cyan). d, e Comparison of VH-VL domains of PGT122 (yellow) and 10-1074 (magenta) with BG18 (blue). The VH-VL domain orientation
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presence of glycans in this region do not notably affect BG18
neutralization (e.g., N133gp120, N137gp120, and N156gp120 glycans;
Fig. 6a and Table 2), despite the roof of the cleft being only ~6–8
Å above the V1-loop site. In comparison, the surface of 10-1074
in the comparable region is neutral and does not exhibit a cleft
architecture, and only minimally contacts the V1-loop backbone
through R94LC (Supplementary Figure 10). Taken together, these
observations may explain BG18’s increased potency, as BG18 can
engage multiple glycan and protein component regions of gp120
(Supplementary Data 1).
Discussion
Structures of bNAbs complexed with HIV-1 Env trimers have
helped elucidate the molecular correlates for anti-HIV-1 antibody
breadth and potency. Here we report four crystal structures of the
highly potent V3/N332gp120 bNAb BG18 bound to natively gly-
cosylated clade A and clade B Envs (Fig. 1a–c). Our structures of
clade A BG505 and clade B B41 HIV-1 strains represent only the
second example of fully and natively glycosylated Env crystal
structures, with the first being BG505 complexed with another
V3/N332gp120 bNAb, 10-1074, and with the CD4bs bNAb
IOMA25. Given the crucial role the Env glycan shield plays in
HIV-1’s immune evasion strategies13,58, the prevalence of bNAbs
that interact with complex glycans18,25,58, and the importance of
complex glycans in bNAb maturation46, solving structures
containing both complex and high-mannose glycans provides a
more complete picture of bNAb recognition of Env epitopes. The
newly identified BG18-Env-35O22 crystal lattice system packs
solely through Fab interactions (Table 1 and Supplementary
Figure 3e), similar to crystals of previously described Env-bNAb
complexes25,27, thus providing an additional system to study
HIV-1 Env diversity. Moreover, the improvement in resolution
from 4.1 Å using conventional crystals to 3.8 Å resolution by
exposing smaller crystal volumes using an XFEL (Supplementary
Figure 2) offers the potential to examine natively glycosylated Env
trimer–Fab structures to higher resolutions. The demonstration
that two HIV-1 Env trimers (BG505 and B41) can be crystallized
in different crystal packing lattices without converting their
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annealed omit maps calculated with phases from models with glycan coordinates omitted to reduce potential phase bias (gray mesh)
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glycans to exclusively high-mannose forms provides an impetus
for further crystallization efforts using natively glycosylated
HIV-1 Envs. Resulting crystal structures can be compared to
natively glycosylated Env structures determined by cryo-EM38, a
method that does not require crystallization and can therefore be
used for heterogeneously glycosylated samples.
Our structures were consistent with previous evidence that
BG18 binds with a distinct orientation compared to the prototype
PGT121/10-1074 bNAbs in the V3/N332gp120 glycan-targeting
family47 and showed extensive interactions with both protein
and glycan components of gp120 (Fig. 1d). BG18’s CDRH3
interactions with GDIR and the N332gp120 glycan are conserved
with other V3/N332gp120 bNAbs (Supplementary Figure 5),
Table 2 Glycan and sequence preference for V3/N332gp120 targeting bNAbs in the presence of N332gp120 glycan
IC50 values (µg/mL)a
BG18 10-1074 PGT122 PGT121
+392 0.05 (n= 67) 0.07 (n= 65) 0.21 (n= 88) 0.13 (n= 224)
−392 0.21 (n= 13) 0.08 (n= 201) 0.16 (n= 16) 0.07 (n= 65)
+386 0.05 (n= 67) 0.07 (n= 234) 0.20 (n= 90) 0.12 (n= 255)
−386 0.17 (n= 13) 0.08 (n= 32) 0.20 (n= 14) 0.08 (n= 34)
+301 0.06 (n= 78) 0.07 (n= 262) 0.17 (n= 99) 0.10 (n= 283)
−301 0.60 (n= 2)b 0.39 (n= 4) 12.30 (n= 5) 12.54 (n= 6)
+156 0.06 (n= 73) 0.07 (n= 253) 0.19 (n= 97) 0.12 (n= 276)
−156 0.05 (n= 7) 0.08 (n= 13) 0.46 (n= 7) 0.11 (n= 13)
+137 0.02 (n= 9) 0.06 (n= 55) 0.10 (n= 15) 0.07 (n= 60)
−137 0.07 (n= 71) 0.08 (n= 211) 0.23 (n= 89) 0.13 (n= 229)
+133 0.03 (n= 18) 0.07 (n= 65) 0.06 (n= 23) 0.10 (n= 70)
−133 0.08 (n= 62) 0.08 (n= 201) 0.28 (n= 81) 0.12 (n= 219)
D325gp120 0.05 (n= 65) 0.05 (n= 209) 0.11 (n= 89) 0.07 (n= 229)
N325gp120 0.10 (n= 12) 0.12 (n= 47) 4.82 (n= 12) 0.41 (n= 49)
a Geometric mean IC50 values were calculated using HIV Antibody Database74, where n= # of strains. All values were calculated including only strains containing the N332gp120 PNGS
b Analysis done on the only two strains that met the tested criteria
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Fig. 5 Comparison of GDIR recognition by BG18 and 10-1074. a Cartoon and stick representation of BG18 CDRH3 (dark blue), BG18 CDL2 (light blue), and
gp120 (gray; residues 318-330). Electron density contoured at 1σ from 2Fobs−Fcalc final refined electron density map with −100 Å2 B-sharpening is shown
(gray mesh). b BG18 interactions with the gp120 GDIR motif (G324gp120-D325gp120-I326gp120-R327gp120) at the base of the V3-loop. In common with the
PGT121-like bNAbs, CDRH3 E111HC forms a potential salt bridge with R327gp120, while CDRH3 Y104HC stacks against D325gp120. In addition, CDRL2
residues S53LC and Q54LC engage D325gp120 forming potential H-bond interactions. c Comparison of BG18 (light blue) and 10-1074 (pink; PDB 5T3Z
(http://dx.doi.org10.2210/pdb5T3Z/pdb)) interactions with D325gp120 in the GDIR motif. Engagement of the carboxylate group of D325gp120 is achieved
by residues in CDRL2 (BG18) or serine residues in CDRs L1 and L3 (10-1074). Potential H-bonds represented as dashed lines. d Alignment of sequences of
inferred germline and mature light chains of BG18 and 10-1074. The LV3-21*02 germline V gene segment is used for both 10-1074 and PGT121-like
antibodies40. Red asterisks indicate residues involved in D325gp120 recognition in the GDIR motif as shown in c
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serving as the main driver for epitope recognition (Figs 3c and
5b). Strikingly, the D3-3 gene for BG18/10-1074/PGT121 bNAbs
that encodes a CDRH3 consensus structural motif responsible for
N332gp120 glycan interactions plays a role analogous to the VH1-2
gene for VRC01-like bNAbs24,59,60 for epitope targeting. This
common feature, which unites the PGT121 and BG18 bNAb
families, suggests that it provides the key interaction in the initial
binding of their unmutated ancestor precursors to Env. Inter-
estingly, this common interaction occurs despite different orien-
tations for the rest of the VH-VL domains (Fig. 4a, b). For
example, unlike other V3/N332gp120 bNAbs, BG18’s light chain
CDR loops straddle the V1-loop of gp120 (Fig. 6), increasing
surface contact with gp120 protein components. In addition,
BG18’s interactions with gp120 N-glycans differ from the
PGT121-like family in both engagement and ability to retain
potent neutralization properties. For instance, despite extensive
interactions with glycans at positions N392gp120 and N386gp120
(Fig. 4a, e and Supplementary Data 1), BG18 can potently neu-
tralize HIV-1 strains lacking these glycans, by contrast to the
more weakly neutralizing V3/N332gp120 bNAb, PGT135, which
relies on N332gp120, N392gp120, and N386gp120 glycans for its anti-
HIV-1 activity44 (Table 2). Consistent with this observation,
analysis of neutralization by BG18 and PGT121/10-1074
family bNAbs of HIV-1 strains including the N332gp120 glycan,
but with and without glycans known to interact with bNAbs
targeting the V3/N332gp120 epitope, showed that BG18 and 10-
1074 retained their anti-HIV-1 potency (mean IC50s < 0.6 µg/
mL), whereas PGT121/PGT122 potency was abrogated upon
removal of the N301gp120 glycan (Table 2). Furthermore,
PGT122 showed sensitivity to D325Ngp120 mutations in the GDIR
peptide motif. Taken together, these differences illustrate the
divergence of solutions evolved by bNAbs to target this epitope,
and BG18’s successful strategies to accommodate Env sequence
diversity.
Recent studies showed that priming with designed SOSIP Env
trimers that bind weakly to the common inferred germline
sequence (iGL) of PGT121 and 10-107450 could elicit bNAbs
resembling PGT121 in PGT121 iGL Ig knock-in mice49.
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Fig. 6 BG18 contacts with gp120 V1-loop. a Surface and cartoon representation of BG18 VH (dark blue) and VL (light blue) loops involved in gp120 V1-loop
(gray; residues 128–158, disordered residues depicted as dashed red line) interactions. Electron density contoured at 1σ from a 2Fobs−Fcalc composite
annealed omit map is shown (gray mesh). Glycans at position N133gp120 and N156gp120 are shown. b Cartoon and stick representation of residue
interactions between BG18 VL domain (light blue) and the gp120 V1-loop (gray). Potential H-bonding occurs between T139gp120 and BG18 T30LC in the
CDRL1 loop. In addition, BG18 W67LC in FWRL3 stacks against I138gp120. BG18 contacts with gp120 positions 138 and 139 are likely specific to Envs with V1
characteristics similar to BG505, since similar conformations were not observed in our BG18-B41 structure. H-bonds and pi-stacking are indicated by black
dashed lines. Red asterisk on N137gp120 indicates a PNGS. c Electrostatic surface potentials with red indicating negative electrostatic potential and blue
indicating positive electrostatic potential for BG18 shown with cartoon and stick representation of nearby gp120 elements. BG18 includes a positively
charged cleft in the vicinity of the gp120 V1-loop (dashed line indicates disordered region), which may provide increased protein–protein interactions with
the gp120 surface in HIV-1 strains harboring charged residues in the V1-loop
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However, the iGL of BG18 did not bind detectably to the tightest-
binding designed priming immunogen 11MUTB (Supplementary
Figure 11a), which can be rationalized by one of several
differences in BG18 and PGT121/10-1074 recognition of Env.
First, mature BG18 CDRL2 residues are involved in GDIR
recognition with S53LC and Q54LC engaging D325gp120 of GDIR
(Fig. 5b). Comparison of iGL and mature BG18 CDRL2 amino
acid sequences showed that four of five residues were mutated
(50YKDSE54 vs. 50SRSSQ54, respectively) (Fig. 5d). Not only does
the germline CDRL2 have increased bulk, but also acidic residues
flank S53LC, which interacts with D325gp120. In contrast, iGL
sequences for CDRL1/3 in PGT121/10-1074 show conservation of
serines responsible for interacting with D325gp120 in GDIR and
flanking residues (Fig. 5d). Thus, since the 11MUTB priming
immunogen contains no substitutions in GDIR, BG18 iGL likely
shows a reduced ability to interact with this region compared
with PGT121/10-1074 iGLs. An additional predicted impediment
to iGL BG18 binding to 11MUTB is the relative proximity of light
chain CDRs to the gp120 V1-loop (Fig. 6). Since the CDRs are the
most heavily substituted between iGL and mature sequences,
altering the chemical properties of this cleft could negatively
affect binding. Moreover, 11MUTB harbors seven mutations in
the V1-loop necessary for iGL PGT121 binding50, which likely
clash with iGL BG18 given its V1-loop interactions (Supple-
mentary Figure 11b). Finally, mature BG18 is heavily substituted
compared to iGL sequences (35 and 26 heavy chain and light
chain amino acid mutations, respectively). Previous structural
studies of a PGT121 intermediate bound to BG505 Env showed
that orientations are defined early during maturation and that
differences in amino acid composition can alter antibody foot-
prints on gp12031. Thus, it is possible that the conformation of
iGL BG18 is incompatible with 11MUTB binding.
Although eliciting BG18-like bNAbs would require a different
set of designed immunogens than being used for PGT121/10-
1074 bNAbs49,50, they might be easier to elicit because of a
shorter CDRH3 than PGT121/10-1074 bNAbs. By elucidating the
molecular details of BG18’s distinct interaction with the V3/
N332gp120 epitope, the structural information reported here will
facilitate future immunogen design efforts.
Methods
Protein expression and purification. Fabs from BG18 (including a N26QHC
substitution47), 35O22, and IOMA IgGs were produced as previously described37.
Briefly, Fabs were expressed by transiently transfecting HEK293-6E cells
(National Research Council of Canada) with vectors encoding the appropriate light
chain and C-terminal 6x-His tagged heavy chain genes. Secreted Fabs were
purified from cell supernatants using Ni2+-NTA affinity chromatography
(GE Healthcare), followed by size exclusion chromatography (SEC) with a
Superdex200 16/60 column (GE Healthcare). Purified Fabs were concentrated and
maintained at 4 °C in storage buffer (20 mM Tris pH 8.0, 150 mM NaCl, and 0.02%
sodium azide).
Genes encoding BG505 SOSIP.664 gp14020 or B41 SOSIP.664 gp14061 trimers
were stably expressed in CHO Flp-InTM cells (Invitrogen) as described51 using cell
lines kindly provided by John Moore (Weill Cornell Medical College). Plasmids
encoding the BG505 SOSIP.664 gp140 N392 gene variant (see Supplementary
Table 1 for primer sequences) was transiently expressed in HEK293-6E cells
(National Research Council of Canada) as previously described22. In both cases,
secreted SOSIP trimers expressed in the absence of kifunensine were isolated from
cellular supernatants using 2G12 immunoaffinity chromatography by covalently
coupling 2G12 IgG monomer to an activated-NHS Sepharaose column (GE
Healthcare). Trimers were eluted using 3 M MgCl2 and immediately dialyzed into
storage buffer before SEC purification with a Superdex200 16/60 column (GE
Healthcare) against the same buffer. Peak fractions pertaining to SOSIP trimers
were pooled and repurified over the same column and buffer conditions. Twelve
1.0-mL fractions were stored separately at 4 °C.
Crystallization of BG18–Env complexes. Complexes for crystallization were
produced by an overnight incubation of SOSIP with BG18 and 35O22 or IOMA
Fabs at a 1:1:1 molar ratio, and subsequently concentrated to 5–8 mg/mL by
centrifugation with a 30-kDa concentrator (Amicon). Initial matrix crystallization
trials were performed at room temperature using the sitting drop vapor diffusion
method by mixing equal volumes of protein sample and reservoir using a TTP
LabTech Mosquito robot and commercially available screens (Hampton Research
and Qiagen). Initial hits were optimized and crystals were obtained for BG18-
BG505-35O22 and BG18-B41-35O22 in 0.1 M Tris pH 8.0, 5% Tacismate pH 8.0,
and 14% polyethylene glycol (PEG) 3350 at 20 °C. BG18-BG505-IOMA crystals
were obtained in 0.1 M citric acid pH 3.7, 16% PEG 3350 at 20 °C. Crystals were
cryo-protected stepwise with reservoir and a final 20% v/v glycerol concentration
before being cryopreserved in liquid nitrogen.
Structure determination and refinement. Conventional X-ray diffraction data
were collected for BG18-Env complexes at the Stanford Synchroton Radiation
Lightsource (SSRL) beamline 12-2 on a Pilatus 6M pixel detector (Dectris). Data
from a single crystal for each complex were indexed and integrated in XDS62, and
merged with AIMLESS in the CCP4 software suite63. Structures were determined by
molecular replacement in PHASER64 using a single search with coordinates of an a
glycosylated gp120-4 protomer (PDB 5T3Z (https://doi.org/10.2210/pdb5T3Z/
pdb)), BG18 Fab (PDB 5UD9 (https://doi.org/10.2210/pdb5UD9/pdb)), and 35O22
Fab (PDB 4TOY (https://doi.org/10.2210/pdb4TOY/pdb)) or IOMA Fab (PDB
5T3Z (https://doi.org/10.2210/pdb5T3Z/pdb)). Models were refined using B-factor
refinement in CNS65 and Phenix56, followed by several cycles of manual building
with B factor sharpening in Coot55,66. Glycans were initially interpreted and
modeled using Fo−Fc maps calculated with model phases contoured at 2σ, followed
by 2Fo−Fc simulated annealing composite omit maps in which modeled glycans
were omitted to remove model bias56. N-linked glycans identified at individual
PNGSs in our crystallographic studies on both BG505.664 and B41.664 SOSIP
trimers were generally consistent with the mixture of glycans observed by mass
spectroscopy18,57 and previous crystallographic studies of a natively and fully gly-
cosylated Env trimer25. Therefore, modeling of complex-type glycans at positions
N88gp120 and N156gp120 were primarily determined by the presence of electron
density characteristic of a core fucose, which when modeled, slightly lowered Rfree
values. Additional details of glycan modeling and coordinate refinement were fol-
lowed as previously described25,67. Inclusion of higher resolution data with weak
intensities improved refinement behavior and stereochemistry as described68.
XFEL diffraction experiments were performed at the MFX endstation of LCLS
using a standard goniometer setup48, 9.5 keV X-ray pulses with 40 fs duration and a
5-µm beam focus at the crystal interaction point. Diffraction images were recorded
on a Rayonix MX325 detector data and were integrated with IOTA69 using the data
reduction algorithms implemented in cctbx.xfel70. Of the 627 collected images, 589
contained discernible diffraction; of these, 570 were successfully integrated and
yielded correct crystal symmetry and unit cell values. Scaling, post-refinement, and
merging was carried out using PRIME71. Of the 570 integrated diffraction images,
526 were included in the final merged dataset, which was complete (99.1%) to 3.8 Å,
and exhibited good multiplicity (9.2-fold) and reasonable merging statistics
(Table 1). Phases were generated by molecular replacement, using our refined 4.1 Å
synchrotron structure with glycans omitted as a search model.
Superposition and figures were rendered using PyMOL (Version 1.5.0.4
Schrodinger, LLC), and protein electrostatic calculations were achieved using APBS
and PDB2PQR webservers72. BSAs were determined with PDBePISA using a 1.4-Å
probe73. Potential hydrogen bonds were assigned using a distance of <3.6 Å and an
A-D-H angle of >90°, while the maximum distance allowed for a van der Waals
interaction was 4.0 Å. Putative H-bonds, van der Waals assignments, and total BSA
should be considered tentative, owing to the relatively low structure resolutions.
Binding experiments. SPR experiments were carried out on a Biacore T100
(Biacore) using a standard single-cycle kinetics method as previously descri-
bed22,37. Briefly, a CM5 chip, primarily amine coupled with Protein A, was used to
immobilize 8ANC195 IgG, a gp120-gp41 interface bNAb37. Remaining Protein A
sites were blocked with 1 µM human Fc. BG505 HIV-1 SOSIP trimers were cap-
tured by injecting 10 µM solutions at a flow rate of 30 µL/s for 180 s. Mature BG18
Fab was injected at decreasing concentrations (3-fold dilution series with a starting
top concentration of 110 nM) at 30 µL/s for 60 s and allowed to dissociated for 300
s. Kinetic analyses were done after subtraction of reference curves to obtain ka, kd,
and KD values for a 1:1 binding model with or without a bulk refractive index
change correction as appropriate (Biacore T200 Evaluation software).
An ELISA to evaluate binding of mature and iGL BG18 IgG to 11MUTB SOSIP50
was performed by coating of High-Bind 96-well plates (Corning #9018) with 50 µL
per well of a 2-µg/mL solution of purified 11MUTB in PBS overnight at 4 °C. Plates
were washed six times with washing buffer (1× PBS with 0.05% Tween 20 (Sigma-
Aldrich)) and incubated in blocking buffer (1× PBS with 1% non-fat milk) for 1 h at
room temperature (RT). Immediately after blocking, IgGs were added in blocking
buffer and incubated for 2 h at RT. Antibodies were assayed at a 5-µg/mL starting
dilution and seven additional 3-fold serial dilutions. Plates were washed six times
with washing buffer and then incubated with anti-human IgG secondary antibody
conjugated to horseradish peroxidase (HRP) (Jackson Laboratories) in washing
buffer at a 1:5000 dilution. Plates were developed by addition of the HRP substrate,
ABTS (Life Technologies), and absorbance was measured at 405 nm with an ELISA
microplate reader (FluoStar Omega, BMG Labtech).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03632-y
10 NATURE COMMUNICATIONS |  (2018) 9:1251 | DOI: 10.1038/s41467-018-03632-y | www.nature.com/naturecommunications
Data availability. Coordinates and structure factors reported in this manuscript
have been deposited in the Protein Data Bank with accession codes 6CH7, 6CH8,
6CH9, and 6CHB. Other data are available from the corresponding author upon
reasonable request.
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